Results you can trust
The QuantStudio™ Dx instrument’s proven performance, security, and reliability—combined with the outstanding sensitivity and specificity of the Quidel® Assays including Molecular Direct C. difficile Influenza A + B and Respiratory syncytial virus (RSV) and human metapneumovirus hMPV assays—help ensure that the right answer is delivered the first time, and every time.
Flexibility you want
In Test Development Mode, the QuantStudio™ Dx instrument enables the creation of new assays in 96-or 384-well plates, and qPCR Microfluidic Card formats provide easily interchangeable thermal cycling blocks to accommodate your lab’s throughput assay development. The 96-well fast block can be used in IVD mode.
A simplified instrument and assay workflow as well as intuitive software makes the entire test—from processing to reporting—efficient and cost-effective. Plus, it frees up highly trained operators to perform more complex tasks. The Quidel® Molecular Direct C. difficile Assay is currently the only approved assay for use in the United States on the QuantStudio™ Dx Instrument with additional assays in development.
Diagnostics platform that grows with you
Through our partnership with Quidel® Corporation, we are in the process of developing a growing list of assays to accommodate your testing needs. Starting with the Molecular Direct C. difficile, Influenza A + B and Respiratory syncytial virus (RSV) and human metapneumovirus hMPV assays in the US, the expanded assay menu in the future may include tests for HSV 1+ 2/VZV and other infectious diseases, and also for oncology and inherited diseases.